Medication info
Janugliptin Met Formulation 50/1000 mg

Janugliptin Met Formulation 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202200905 · Approved 2022.03.02 · Insurance code 663608760

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control disorder
View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. It is effective for patients starting diabetes medications for the first time or those who find it difficult to control blood sugar with monotherapy. Moreover, it can be used as an alternative when blood sugar control is inadequate with monotherapy of metformin or sitagliptin, or when both medications are used together. In cases where control is difficult with combination therapy of metformin and sulfonylurea, or metformin and thiazolidinedione, this medication can be added to improve blood sugar. If blood sugar control is inadequate when using insulin with metformin, this drug can be administered concurrently to assist in managing blood sugar. Therefore, this medication is utilized to improve blood sugar control across various stages of treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).

Precautions

This medication may cause severe allergic reactions, so if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur, it should be immediately discontinued and medical consultation sought. During treatment, inflammation of the pancreas (pancreatitis) may arise; if symptoms like abdominal pain, vomiting, or loss of appetite occur, consult a physician immediately. Patients with severe renal impairment, heart failure, acute myocardial infarction, or other serious conditions should not use this medication, and may need to temporarily discontinue it prior to certain tests. It is safest for women who are pregnant, potentially pregnant, or breastfeeding to refrain from using this medication. This medication can induce hypoglycemia, so caution is needed if meals are skipped, there are irregular eating habits, or excessive exercise occurs. Regular kidney function and blood tests should be performed during treatment, and it is advisable to check vitamin B12 levels as well. Alcohol consumption may increase the risk of side effects from this medication, so drinking should be avoided while on this treatment. If surgery is planned, this medication should be temporarily halted 48 hours before the procedure and resumed only after kidney function has been confirmed to be normal post-surgery. Gastrointestinal disturbances such as diarrhea, nausea, vomiting, abdominal pain, headache may occur during treatment, and signs of hypoglycemia may also need attention. Rarely, severe joint pain, skin rash, or blistering skin diseases may occur; immediate consultation with a physician is necessary if symptoms are severe. This medication can have interactions with other antidiabetic drugs or specific medications; therefore, it is essential to inform healthcare providers of any other ongoing medications. Elderly patients or those with reduced kidney function should be particularly cautious during use, requiring dose adjustments and regular monitoring. In case of overdose, immediate medical attention should be sought, and some components can be removed by dialysis.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling manifestations, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, loss of appetite, weight loss, neutrophilia, increased serum creatinine, elevated liver enzymes, acute renal failure, decreased appetite, itching, dizziness, hypoglycemia, severe hypoglycemia, decreased serum vitamin B12, rash, urticaria, cutaneous vasculitis, bullous pemphigoid, acute renal failure, dyspnea, unstable angina, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container that allows for good air circulation, and it is recommended to be stored at room temperature between 1 to 30 degrees Celsius. This storage method will help maintain the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.